Brief: Vivos Therapeutics Reports Q1 Net Loss of $0.07 per Share
08/06/2023 22:29
June 8 (Reuters) - Vivos Therapeutics Inc VVOS.O :
* VIVOS THERAPEUTICS INC - QTRLY OPERATING EXPENSES
DECREASED 20%
AS COST CUTTING INITIATIVES TAKE HOLD (ADDS PERIOD)
* VIVOS THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND PROVIDES OPERATIONAL UPDATE
* VIVOS THERAPEUTICS INC - CASH AND CASH EQUIVALENTS WERE
$7.0
MILLION AT MARCH 31, 2023
* VIVOS THERAPEUTICS INC Q1 EARNINGS PER SHARE USD -0.07
Recent news on Vivos Therapeutics
See all newsBrief: Vivos Therapeutics Closes Acquisition Of Stake In Sod Sciences And 50% Interest In Pseudohypoxia Test, Opening A Potential Path To Access More Than 325,000 New Patients Through The Aha Channel
Brief: Vivos Therapeutics - Audit Reports For Fy2025 And Fy2024 Include Substantial Doubt About Going Concern
Brief: Vivos Therapeutics And South Palm Cardiovascular Associates Sign Definitive Agreements To Launch Regional Sleep Testing And Treatment Center
Vivos Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Vivos Therapeutics Q2 revenue rises 35% on service growth